ADVERTISEMENT
Research & Development
From a biofoundry network and pharma industry backed AI research organization to a small-molecule repurposed drug in Duchenne’s muscular dystrophy, experts discuss a number of advances underway as India seeks to move up the innovation ladder.
Multiple Chinese biotechs are seeking to raise new funds through IPOs on the Hong Kong and Beijing stock exchanges to support international clinical trials for their first-in-class molecules.
An India-EU trade deal sets ground for a free trade agreement to lower tariffs on pharma, though an investment protection agreement – likely influencing data exclusivity – will be concluded later. Will the US now reconsider its India tariffs?
Obesity drug MariTide and olpasiran in cardiovascular disease will not produce Phase III data until 2027, but Scrip spoke with Amgen EVP of R&D James Bradner about those programs, near-term pivotal readouts and dealmaking to boost research capabilities.
EIT Health has helped 3,000 start-ups and SMEs scale across Europe and supported over 120 innovations to launch. Inspired by the US MIT, the EIT Health program is on a mission to raise awareness of its value to healthtech innovators as it embarks on new methods of funding its own activities.
The company said amorphous rifaximin solid soluble dispersion did not meet the primary endpoint in two Phase III RED-C trials in the prevention of hepatic encephalopathy in patients with cirrhosis.
The Paris-headquartered giant has heralded data from two new Phase III trials of the anti-OX40L antibody but there are still concerns over its level of efficacy.
Generics Bulletin reviews global regulatory developments across the world.
The company announced that the Phase III ROSELLA trial in platinum-resistant ovarian cancer met its overall survival primary endpoint.
Antti Vuolanto, CEO of Herantis Pharma, discusses the significant unmet need in Parkinson’s disease and outlines Phase II plans for the company’s lead asset HER-096.
Biogen’s head of development reflects on transforming company strategy, surviving the Aduhelm crisis and building sustainable growth through disciplined portfolio management.
Medable pivots to agentic AI targeting clinical development's 80% manual labor bottleneck, aiming to double CRA efficiency and unlock capacity for 9,000 waiting drug candidates.